DK0939590T3 - Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener - Google Patents
Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegenerInfo
- Publication number
- DK0939590T3 DK0939590T3 DK97942543T DK97942543T DK0939590T3 DK 0939590 T3 DK0939590 T3 DK 0939590T3 DK 97942543 T DK97942543 T DK 97942543T DK 97942543 T DK97942543 T DK 97942543T DK 0939590 T3 DK0939590 T3 DK 0939590T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- administration
- nucleic acid
- gene therapy
- cell genes
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 238000001415 gene therapy Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 1
- 230000010307 cell transformation Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/717,084 US6225290B1 (en) | 1996-09-19 | 1996-09-19 | Systemic gene therapy by intestinal cell transformation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0939590T3 true DK0939590T3 (da) | 2006-07-24 |
Family
ID=24880656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97942543T DK0939590T3 (da) | 1996-09-19 | 1997-09-18 | Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener |
Country Status (10)
Country | Link |
---|---|
US (4) | US6225290B1 (da) |
EP (1) | EP0939590B1 (da) |
JP (1) | JP2001502303A (da) |
AT (1) | ATE320186T1 (da) |
AU (1) | AU729457B2 (da) |
CA (1) | CA2264744A1 (da) |
DE (1) | DE69735496T2 (da) |
DK (1) | DK0939590T3 (da) |
ES (1) | ES2256896T3 (da) |
WO (1) | WO1998011779A1 (da) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US7749215B1 (en) * | 1998-02-05 | 2010-07-06 | Biosense, Inc. | Intracardiac cell delivery and cell transplantation |
US20030129750A1 (en) * | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
EP1093457B8 (en) | 1998-03-19 | 2011-02-02 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
CZ295108B6 (cs) | 1998-03-20 | 2005-05-18 | Benitec Australia Ltd | Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
AU3739999A (en) * | 1998-05-06 | 1999-11-23 | Pharmacia & Upjohn Company | Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate |
JPH11335269A (ja) | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
EP1889914A1 (en) * | 1999-02-19 | 2008-02-20 | Engene, Inc. | Compositions for gene therapy of diabetes |
EP1153131B1 (en) * | 1999-02-19 | 2007-09-26 | enGene, Inc. | Compositions for gene therapy of diabetes |
WO2000050620A2 (en) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
WO2000051424A2 (en) * | 1999-03-04 | 2000-09-08 | Ppl Therapeutics (Scotland) Ltd. | Genetic modification of somatic cells and uses thereof |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US6953658B2 (en) | 2000-03-09 | 2005-10-11 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer |
NZ521199A (en) * | 2000-03-13 | 2004-11-26 | Engene Inc | Mucosal cells producing nutrient-regulated protein expressed by a transgene comprising an expression control element linked with a nucleic acid encoding protein, for treating diabetes |
IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
GB0010630D0 (en) * | 2000-05-04 | 2000-06-21 | Univ Wales Medicine | Sequence |
AU2001282856A1 (en) | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
WO2002000939A2 (en) | 2000-06-28 | 2002-01-03 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
US20020151068A1 (en) * | 2001-01-03 | 2002-10-17 | Board Of Regents, The University Of Texas System | Compositions and methods for the diagnosis and treatment of organophosphate toxicity |
CN1564826A (zh) | 2001-02-09 | 2005-01-12 | 人类基因组科学公司 | 人类g蛋白趋化因子受体(ccr5)hdgnr10 |
WO2002080852A2 (en) * | 2001-04-04 | 2002-10-17 | Digital Gene Technologies, Inc. | Genes expressed in intestinal epithelium and peyer's patch m cells |
EP2228389B1 (en) | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
WO2002083080A2 (en) * | 2001-04-17 | 2002-10-24 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
KR20030022094A (ko) * | 2001-05-24 | 2003-03-15 | (주)휴먼디엔에이테크놀로지 | 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체 |
AU2002365188A1 (en) * | 2001-11-07 | 2003-07-30 | Musc Foundation For Research Development | Nucleic acid delivery and expression |
US20030135195A1 (en) * | 2002-01-16 | 2003-07-17 | Oscar Jimenez | Highly lubricious hydrophilic coating utilizing dendrimers |
ATE505201T1 (de) | 2002-02-14 | 2011-04-15 | Univ Leland Stanford Junior | Enzymbehandlung von nahrungsmitteln für zöliakie- sprue |
AU2003265228A1 (en) * | 2002-03-12 | 2003-12-22 | Surface Logix, Inc. | Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound |
US7374930B2 (en) * | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
US7977098B2 (en) | 2002-05-31 | 2011-07-12 | Children's Hospital Medical Center | Antigenic binding patterns of norovirus to human histo-blood group antigens |
ATE498403T1 (de) * | 2002-05-31 | 2011-03-15 | Childrens Hosp Medical Center | Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren |
US20040016013A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
US20040014704A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent induces tolerance |
US20040014698A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
CA2503437A1 (en) * | 2002-10-24 | 2004-05-06 | Biogen Idec Ma Inc. | High expression locus vector based on ferritin heavy chain gene locus |
US20050026859A1 (en) * | 2002-11-12 | 2005-02-03 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
US20080026077A1 (en) * | 2002-11-12 | 2008-01-31 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
US20050169995A1 (en) * | 2003-10-03 | 2005-08-04 | Kuo Calvin J. | Modulation of gastrointestinal epithelium proliferation through the Wnt signaling pathway |
US20050208032A1 (en) * | 2004-01-16 | 2005-09-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
US7981414B2 (en) * | 2005-12-20 | 2011-07-19 | Cephalon Australia Pty Ltd | Anti-inflammatory dAb |
WO2008020318A2 (en) * | 2006-03-30 | 2008-02-21 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
US20100310522A1 (en) * | 2007-11-26 | 2010-12-09 | Plant Bioscience Limited | Novel Polypeptides Having Endolysin Activity and Uses Thereof |
WO2009149191A2 (en) | 2008-06-03 | 2009-12-10 | University Of Rochester | Methods of treating inflammatory intestinal disease and managing symptoms thereof |
US20100068153A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo activatable final dosage form |
US20100068233A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
US8753677B2 (en) * | 2008-09-16 | 2014-06-17 | The Invention Science Fund I, Llc | Ex vivo modifiable multiple medicament final dosage form |
US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
US20100068235A1 (en) * | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
US20100068152A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable particle or polymeric based final dosage form |
US20100068254A1 (en) * | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
GB0908949D0 (en) | 2009-05-26 | 2009-07-01 | Plant Bioscience Ltd | Novel polypeptides having endolysin activity and uses thereof |
WO2010144602A2 (en) | 2009-06-09 | 2010-12-16 | Children's Hospital Medical Center | Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use |
US9321803B2 (en) | 2013-07-12 | 2016-04-26 | Children's Hospital Medical Center | Compositions and methods for inhibiting norovirus infection |
HUE054471T2 (hu) | 2014-04-01 | 2021-09-28 | Rubius Therapeutics Inc | Immunmodulációs módszerek és készítmények |
US20160160229A1 (en) * | 2014-12-09 | 2016-06-09 | THC Farmaceuticals, Inc. | Methods of producing antibody-rich cannabis and honeysuckle plants |
JP2020515531A (ja) | 2017-03-28 | 2020-05-28 | チルドレンズ ホスピタル メディカル センター | ノロウイルスs粒子ベースのワクチンならびにその作製および使用方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643579A (en) * | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US6241982B1 (en) * | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
JPH04504950A (ja) | 1988-11-23 | 1992-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 位置特異的挿入ベクターおよびこれを用いた方法 |
DK0465529T3 (da) | 1989-03-21 | 1998-10-05 | Vical Inc | Ekspression af exogene polynukleotidsekvenser i et hvirveldyr |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
EP0800830A3 (en) | 1989-11-03 | 1999-03-17 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
WO1993019660A1 (en) | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
WO1994016057A1 (en) * | 1992-12-31 | 1994-07-21 | Dana-Farber Cancer Institute, Inc. | Enhancer sequence for modulating expression in epithelial cells |
SG54115A1 (en) | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
CA2162497A1 (en) | 1993-06-10 | 1994-12-22 | Sheila Connelly | Adenoviral vectors for treatment of hemophilia |
US5681744A (en) * | 1995-03-17 | 1997-10-28 | Greenstein; Robert J. | Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters |
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
JPH11507340A (ja) | 1995-06-07 | 1999-06-29 | アルザ コーポレイション | 遺伝子構築物の経口送出 |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
-
1996
- 1996-09-19 US US08/717,084 patent/US6225290B1/en not_active Expired - Lifetime
-
1997
- 1997-09-18 EP EP97942543A patent/EP0939590B1/en not_active Expired - Lifetime
- 1997-09-18 ES ES97942543T patent/ES2256896T3/es not_active Expired - Lifetime
- 1997-09-18 AU AU44221/97A patent/AU729457B2/en not_active Ceased
- 1997-09-18 AT AT97942543T patent/ATE320186T1/de not_active IP Right Cessation
- 1997-09-18 US US09/254,988 patent/US6258789B1/en not_active Expired - Lifetime
- 1997-09-18 DE DE69735496T patent/DE69735496T2/de not_active Expired - Fee Related
- 1997-09-18 JP JP10514853A patent/JP2001502303A/ja not_active Ceased
- 1997-09-18 WO PCT/US1997/016523 patent/WO1998011779A1/en active IP Right Grant
- 1997-09-18 DK DK97942543T patent/DK0939590T3/da active
- 1997-09-18 CA CA002264744A patent/CA2264744A1/en not_active Abandoned
-
2001
- 2001-03-16 US US09/811,323 patent/US6831070B2/en not_active Expired - Fee Related
-
2004
- 2004-08-03 US US10/911,082 patent/US20050026863A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6258789B1 (en) | 2001-07-10 |
ATE320186T1 (de) | 2006-04-15 |
AU4422197A (en) | 1998-04-14 |
US20050026863A1 (en) | 2005-02-03 |
US6831070B2 (en) | 2004-12-14 |
EP0939590A1 (en) | 1999-09-08 |
EP0939590B1 (en) | 2006-03-15 |
EP0939590A4 (en) | 2002-09-04 |
DE69735496D1 (de) | 2006-05-11 |
WO1998011779A1 (en) | 1998-03-26 |
CA2264744A1 (en) | 1998-03-26 |
US6225290B1 (en) | 2001-05-01 |
DE69735496T2 (de) | 2006-09-21 |
JP2001502303A (ja) | 2001-02-20 |
AU729457B2 (en) | 2001-02-01 |
US20020039574A1 (en) | 2002-04-04 |
ES2256896T3 (es) | 2006-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0939590T3 (da) | Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener | |
Martin et al. | Gene transfer to intact mesenteric arteries by electroporation | |
US5821235A (en) | Gene therapy using the intestine | |
US6747014B2 (en) | Compositions and methods for non-parenteral delivery of oligonucleotides | |
Cotti et al. | Healing of apical periodontitis in patients with inflammatory bowel diseases and under anti–tumor necrosis factor alpha therapy | |
JP2003525912A (ja) | 遺伝子送達用核酸製剤および使用方法 | |
DE69914932D1 (de) | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis | |
JPH11502413A (ja) | 分泌腺発現による遺伝子治療 | |
ATE327326T1 (de) | Fhit proteine und nukleinsäuren sowie darauf basierende verfahren | |
CA2227871A1 (en) | Mucosal delivery of polynucleotides | |
HUP9800028A2 (hu) | Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének | |
EA005496B1 (ru) | Растворимый гетеродимерный рецептор цитокина | |
Islamov et al. | Epidural stimulation combined with triple gene therapy for spinal cord injury treatment | |
CN102462837A (zh) | 抗炎组合物 | |
US20120270920A1 (en) | Compositions and methods for treatment of pouchitis | |
Paap et al. | Total recall: intestinal TRM cells in health and disease | |
Li et al. | Electroporation protocols | |
HUP0002913A2 (hu) | Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára | |
Baum et al. | The mouth is a gateway to the body: gene therapy in 21st century dental practice | |
CN108685850A (zh) | 模块化组装的组合生物药物联合递送系统及应用 | |
Schjerling | The basics of gene doping | |
CN104232685A (zh) | 一种可活体成像监测肝脏中NF-κB活性的小鼠模型及其构建方法 | |
CN103173479B (zh) | 一种可活体成像监测肝脏中IFN-β或NF-κB活性的小鼠模型及其构建方法 | |
Morikawa et al. | Impaired G‐CSF production at post‐transcriptional level in a patient with chronic idiopathic neutropenia | |
EP4022039B1 (en) | Activated mesenchymal stem cells for use in treating limb ischemia |